PSCA is a target of chimeric antigen receptor T cells in gastric cancer

Di Wu1,2,3, Jiang Lv2,3,4, Ruocong Zhao2,3,5, Zhiping Wu2,3,4, Diwei Zheng2,3,4, Jingxuan Shi2,3,4, Simiao Lin2,3, Suna Wang2,3, Qiting Wu2,3, Youguo Long2,3, Peng Li2,3,6* and Yao Yao2,3*

Abstract

Background: Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer. However, no previous study has investigated the feasibility of using anti-PSCA CAR-T cells to treat gastric cancer, irrespective of the proven expression of PSCA on the gastric cancer cell surface.

Methods: We determined the expression of PSCA in several primary tumor tissues and constructed third-generation anti-PSCA CAR-T cells. We then incubated anti-PSCA CAR-T cells and GFP-T cells with target tumor cell lines at E:T ratios of 2:1, 1:1, 1:2, and 1:4 to evaluate the therapeutic efficacy of anti-PSCA CAR-T cells in vitro. We also assayed canonical T cell activation markers after coculturing anti-PSCA CAR-T cells with target cell lines by flow cytometry. The detection of a functional cytokine profile was carried out via enzyme-linked immunosorbent assays. We then evaluated the antitumor activity of anti-PSCA CAR-T cells in vivo by establishing two different xenograft GC mouse models.

Results: Anti-PSCA CAR-T cells exhibited upregulated activation markers and increased cytokine production profiles related to T cell cytotoxicity in an antigen-dependent manner. Moreover, anti-PSCA CAR-T cells exhibited robust anti-tumor cytotoxicity in vitro. Importantly, we demonstrated that anti-PSCA CAR-T cells delivered by peritumoral injection successfully stunted tumor progression in vivo. However, intravenous administration of anti-PSCA CAR-T cells failed to reveal any therapeutic improvements.

Conclusions: Our findings corroborated the feasibility of anti-PSCA CAR-T cells and their efficacy against gastric cancer, implicating the potential of applying anti-PSCA CAR-T cells to treat GC patients in the clinic.

Keywords: Chimeric antigen receptor T cells, Gastric cancer, Prostate stem cell antigen, Immunotherapy

Introduction

Gastric cancer is a significant public health issue, as the fourth most common cancer and the third leading cause of cancer death worldwide [1]. The overall patient survival is significantly poor because of late diagnosis and suboptimal therapies. For early diagnosed patients, combinations of chemotherapy, radiation therapy, or target therapy may be recommended, and many cases can be cured [2]. Unfortunately, the disease is usually diagnosed in an advanced stage, with a reduced response rate to preceding therapies, which underscores the urgency of discovering new treatment modalities.

Chimeric antigen receptors (CARs) are genetically modified receptors that redirect T cells to various tumor surface antigens [3]. First generated in the late 1980s and later developed in the early 2010s, a CAR molecule now generally contains an extracellular antigen-binding domain, an intracellular signaling domain, and one or two additional intracellular costimulatory signaling domains [4, 5]. For clinical use, T cells are harvested from either patients or healthy donors, manipulated to express a specific receptor protein, and then infused into patients after...
expansion. Acting as a living drug, CAR-T cell therapy is rapidly emerging as a promising new treatment for hematological and nonhematological malignancies [6]. In 2017, the FDA approved Novartis’s tisagenlecleucel for pediatric B cell precursor acute lymphoblastic leukemia (ALL) and Kite’s axicabtagene ciloleucel for adult diffuse large B cell lymphoma [7, 8], thus pushing forward the development of CAR-T cell therapy. Interests have been increased around the possibility that similar success could be achieved in solid tumors. A growing number of preclinical and clinical trials have been conducted ever since [9–11]. Despite the characterization of EpCAM and claudin as new target antigens in gastric cancer [12, 13], disease heterogeneity remains a substantial obstacle for solid tumor immunotherapy [14], necessitating the identification of alternative antigens.

PSCA, formerly denoted as prostate stem cell antigen, is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Thy-1/Ly-6 family. This antigen has been recognized as a critical marker in several primary cancers, including bladder, prostate, and pancreatic cancers [15]. Existing studies have thoroughly acknowledged the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer [16, 17]. Specifically, a phase I study employing anti-PSCA CAR-T cells for the treatment of patients with metastatic castration-resistant prostate cancer has recently been initiated. Although extensive research applying this target in multiple malignancies has been carried out, no single study has verified the applicability of targeting PSCA in gastric cancer, irrespective of its proven expression on the gastric cancer cell surface [18].

To address the feasibility of using anti-PSCA CAR-T cells to treat GC, we first confirmed PSCA expression in numerous primary GC tissues and multiple cell lines. T cells encoding a PSCA-specific CAR exhibited upregulated activation markers and secreted abundant cytokines critical for T cell immunity upon coculture with BGC-823 cells. Anti-PSCA CAR-T cells also exerted increasing cytotoxicity from low to high E:T ratios. In particular, we showed that the peritumoral application of anti-PSCA CAR-T cells in xenograft GC mouse models imposed efficient tumor control. Altogether, we provided proof-of-principle data for the use of anti-PSCA CAR-T cells in the treatment of gastric cancer.

**Methods**

**Generation of the anti-PSCA lentiviral vector**
The anti-PSCA scFv fragment was derived from the humanized IG8 anti-PSCA antibody [19] and was synthesized by Genscript Co., Ltd. (Nanjing, China) after codon optimization. This fragment was then cloned into a previously reported lentiviral vector containing both CD28 and DAP10 intracellular domains.

**Lentivirus production**
To produce lentivirus particles, 293 T cells cultured in DMEM (Gibco, Life Technologies) were co-transfected with the aforementioned anti-PSCA plasmid together with the packaging constructs psPAX2 and pMD2g using polyethyleneimine (Sigma-Aldrich, St Louis, MO, USA). The supernatant was collected 24 h, 48 h, and 72 h post-transfection and filtered through a 0.45 μm filter.

**Generation and expansion of CAR-T cells**
PBMCs were extracted from whole blood obtained from healthy donors through Ficoll-Hypaque density gradient centrifugation (Fresenius Kabi Norge, AS, Berg i Östfold, Norway), while primary human T cells were isolated from PBMCs by means of negative selection with the Pan-T Isolation Kit (Miltenyi Biotec, Germany) and activated by microbeads coated with anti-human CD3, anti-human CD2, and anti-human CD28 antibodies (Miltenyi Biotec, Germany) at a 1:1 ratio for 48 h. Afterwards, T cells were transected with 293 T cell supernatant containing lentivirus particles for 6–8 h in the presence of 8 μg/ml polybrene (Sigma). Two rounds of transduction were conducted, after which T cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 300 IU/ml interleukin-2 (IL-2), and 1% penicillin/streptomycin.

Peripheral blood mononuclear cells (PBMCs) were generated from healthy donors following informed consent and approved by the Research Ethics Board of Guangzhou Institutes of Biomedicine and Health (GIBH).

**Cell lines and reagents**
293 T cells were used for lentivirus production and were maintained in DMEM (Gibco, Life Technologies) supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine, 50 μM β-mercaptoethanol, 100 IU/ml penicillin, and 100 IU/ml streptomycin. BGC-823 (human gastric adenocarcinoma), KATO III (human gastric carcinoma), and MKN-28 (human gastric carcinoma) cell lines were obtained from IBCB (Shanghai, China) and were cultured in RPMI-1640 complete medium. These cell lines were then transduced with a lentivirus vector coexpressing green fluorescent protein (GFP) and luciferase to generate GL-labeled cells.

**Flow cytometry**
Cells were harvested and suspended in 50 μl 1 x PBS and primary labeled antibodies were added subsequently. The antibodies used included anti-human PSCA APC antibody (clone 75) from Santa Cruz Biotechnology
GM-CSF, and TNF-α collected and analyzed for the secretion of IL-2, interferon-γ (IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were obtained from eBioscience (San Diego, CA, USA), and human macrophage colony-stimulating factor (GM-CSF) were obtained from eBioscience (San Diego, CA, USA). The cell types employed in this experiment included BGC-823, MKN-28, and KATO III cells. Uniform CDX models for CAR-T cell treatment

Cytokine release assays

Enzyme-linked immunosorbent assay (ELISA) kits for IL-2, interferon-γ (IFN-γ), TNFα, and granulocyte-macrophage colony-stimulating factor (GM-CSF) were obtained from eBioscience (San Diego, CA, USA), and all ELISAs were performed following the operation manual. T cells were co-cultured with target cells at an E:T ratio of 1:2 for 24 h. The culture supernatant was then obtained 24 h later by adding 100 μl/well D-luciferin (potassium salt) (Yeasen, China) at 100 μg/ml. The background luminescence was negligible (<1% of the signal from wells containing only target cells). The percentage viability was calculated with the following formula: experimental signal/maximal signal × 100, and the percentage of lysis was normalized to 100% viability.

Cytotoxicity assays

The cytolytic activity of anti-PSCA CAR-T cells against BGC-823-GL, KATO III-GL, and MKN-28-GL cells was evaluated by incubating the target cells with anti-PSCA-expressing T cells at the indicated ratio in triplicate wells of white 96-well plates. Target cell viability was monitored 24 h later by adding 100 μl/well D-luciferin (potassium salt) (Yeasen, China) at 100 μg/ml. The background luminescence was negligible (<1% of the signal from wells containing only target cells). The percentage viability was calculated with the following formula: experimental signal/maximal signal × 100, and the percentage of lysis was normalized to 100% viability.

CDX models for CAR-T cell treatment

Animal experiments were performed in the Laboratory Animal Center of the Guangzhou Institutes of Biomedicine and Health (GIBH). All procedures were undertaken under the approval of the Institutional Animal Care and Use Committee of GIBH. NOD-SCID-IL2Rγ−/− mice were generated as previously described [20]. To develop the cancer xenograft models, NSI mice aged from 6 to 10 weeks were used. All mice were maintained in specific pathogen-free (SPF)-grade cages and provided with autoclaved food and water.

For the BGC-823 cell line-based GC subcutaneous (s.c.) xenograft models, 5×10⁵ tumor cells suspended in 150 μl PBS were injected subcutaneously into the left flanks of NSI mice. When the tumor nodules were palpable, the mice were treated with 2.5×10⁶ GFP-T cells or anti-PSCA CAR-T cells both by intravenous injection and peritumoral injection. Tumor volume was measured twice a week and was on the track record for over 3 weeks by a vernier caliper. For the MKN-28 subcutaneously transplanted xenograft models, 2.5×10⁶ tumor cells were injected, and T cells were delivered at a more challenging time point when tumor size went up to around 100 mm³, except which other procedures were followed by the same instructions as described above.

Statistics

Statistical analysis was performed using GraphPad Prism, Version 7 (GraphPad, Inc., San Diego, CA, USA); p values were calculated by unpaired t-test, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001.

Results

PSCA expression in patient tissues and gastric cancer cell lines

To evaluate the potential of the tumor antigen PSCA as an immunotherapeutic target, we immunohistochemically detected its presence and abundance in eight primary gastric cancer samples (Fig. 1a). Most of the analyzed gastric cancer samples expressed PSCA at various frequencies compared to normal tissues. We also performed flow cytometry in several gastric cancer cell lines. The cell types employed in this experiment included BGC-823, MKN-28, and KATO III cells. Uniform expression of PSCA was detected on the surface of these cells (Fig. 1b). Altogether, these data revealed PSCA as a possible novel target for CAR-T cell therapy in GC.

Generation and characterization of anti-PSCA CAR-T cells

We then constructed a third-generation CAR using a humanized single-chain variable fragment (scFv) derived from a mouse anti-human PSCA antibody and a third-generation lentivirus vector composed of a CD3ζ intracellular domain and two costimulatory domains, those of CD28 and DAP10, as previously described [20] (Fig. 2a). T cells transfected with only enhanced green fluorescent protein (eGFP) served as the control for untransduced CAR expression. Primary human T cells were isolated from peripheral blood mononuclear cells (PBMCs) by magnetic selection and were then activated of CD28 and DAP10, as previously described [20] (Fig. 2a). T cells transfected with only enhanced green fluorescent protein (eGFP) served as the control for untransduced CAR expression. Primary human T cells were isolated from peripheral blood mononuclear cells (PBMCs) by magnetic selection and were then activated for 48 h using CD3/CD28/CD2 beads. CAR expression was detected 48 h after lentivirus transduction by flow cytometry according to the GFP-positive proportion (Fig. 2b). Transduced T cells were cultured for 10 days and achieved a final CD45RO⁺CCR7⁺CD62Lhigh phenotype (Fig. 2c), implicating their presumed sustainable antitumor potential in vivo.
Anti-PSCA CAR-T cells exhibited potent cytotoxicity against GC cell lines

Next, we sought to evaluate the therapeutic efficacy of anti-PSCA CAR-T cells in vitro. To determine the cytotoxicity of transduced T cells in a more delicate and sensitive way, we genetically modified three target cell lines, BGC-823, MKN-28, and KATO III, to express GFP-luciferase. Thus, cell viability could be determined by a luciferase reporter system and an illuminator [21]. We then incubated anti-PSCA CAR-T cells and GFP-T cells with the aforementioned target tumor cell lines at E:T ratios of 2:1, 1:1, 1:2, and 1:4. The results showed that anti-PSCA CAR-T cells exhibited more robust cytotoxicity than GFP-T cells after incubation for 24 h (Fig. 3a). To further investigate the cytokine secretion profile of anti-PSCA CAR-T cells in response to target tumor cells, we collected the culture supernatant from the killing assay described above, and the secreted cytokines were quantified via enzyme-linked immunosorbent assay (ELISA). Cytokines, including interferon-γ (IFN-γ), IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TNFα, which are generally secreted by activated T cells, were examined (Fig. 3b). It was unsurprising to see that anti-PSCA CAR-T cells produced significantly more functional cytokines than control GFP-T cells.

To determine whether anti-PSCA CAR-T cells could be activated by antigen-expressing tumor cells in a target-specific manner, we cultured anti-PSCA CAR-T cells and GFP-T cells with BGC-823 tumor cells at a 1:1 ratio. It has been reported that T cell activation and differentiation can be monitored based on changes in the expression of a series of surface biomarkers [20]. After coculture with target cells for 24 h, a T cell surface marker profile was detected by flow cytometry. It was demonstrated that anti-PSCA CAR-T cells were fully activated after coculture with target tumor cells, as indicated by their upregulation of CD25 and CD69 (Fig. 3c, d). Activated anti-PSCA CAR-T cells also downregulated...
CD62L (Fig. 3c, d), a “homing receptor” that is highly expressed on central memory T lymphocytes after they encounter antigen but is not found on effector memory T lymphocytes. Moreover, CD27, a costimulatory immune checkpoint molecule, was also downregulated on anti-PSCA CAR-T cells (Fig. 3c, d). Collectively, these experiments demonstrated that CAR-T cells targeting PSCA were fully activated after encountering target tumor cells and exhibited robust cytotoxicity by producing traditional cytokines related to T cell cytotoxicity.

**Anti-PSCA CAR-T cells showed productive antitumor activity in vivo**

Having verified their cytokine release, activation, and cytolytic capacity in vitro, we then sought to evaluate the therapeutic efficacy of anti-PSCA CAR-T cells in vivo by establishing subcutaneous xenograft gastric cancer cell lines in NSI mice. BGC-823 cells were first transplanted, and mice were administered GFP-T cells and anti-PSCA CAR-T cells when Tumor nodules were palpable (Fig. 4a). A previous study validated that peritumoral delivery of CAR-T cells demonstrated improved efficacy compared to intravenous delivery in xenograft models targeting mesothelin [20]. Thus, we used both delivery strategies for each kind of CAR-T cell to further ascertain this phenomenon in our study. Tumor volume was measured twice a week. Compared to the mock group, the GFP-T cell-treated groups, and even the group treated with intravenous anti-PSCA CAR-T cells, the group treated with peritumoral anti-PSCA CAR-T cells showed significant antitumor efficacy (Fig. 4b, c). We also detected the percentage of T cell infiltration in the tumor, peripheral blood (PB), and spleen (Fig. 4d, e, f). Then, to further validate the cytotoxicity of anti-PSCA CAR-T cells in vivo, we established another mouse model by subcutaneously transplanting MKN-28 tumor cells and infused CAR-T cell at a more challenging size of ~ 100 mm³, simulating late-stage gastric cancer (Fig. 5a). Anti-CD19 CAR-T cells, universally recognized to eliminate CD19-expressing targets, were used as controls to obviate concerns about the CAR alone. Despite the fact that the heavier tumor burden slightly blunted the CAR-T cell effects, anti-PSCA CAR-T cells still displayed robust antineoplastic capacity when
delivered peritumorally (Fig. 5b, c). However, anti-PSCA CAR-T cells transmitted by intravenous injection showed no significant therapeutic ability against PSCA-expressing tumor masses. To address this issue, we examined the T cell level in different organs after sacrificing the mice. The T cell infiltration proportion in tumors was not significantly different between the anti-PSCA CAR-T cell-treated groups and the control groups (Fig. 5d), regardless of the administration patterns. Only a small proportion of T cells could be detected in tumor tissues. Further analysis of the peripheral blood (PB) and spleen revealed an increased percentage of T cells in the
intravenous injection group compared with the peritumorally injected group (Fig. 5e, f), which is slightly different from the performance seen in the BGC-823 model (Fig. 4e, f). In summary, our data demonstrate the remarkable antitumor efficacy of anti-PSCA CAR-T cells in vivo when they are infused peritumorally.

**Discussion**

Being the third leading cause of global cancer mortality [22], gastric cancer has gradually imposed a considerable health burden around the world [17, 23]. Traditional treatments such as surgery are only available for early-stage gastric cancer [24], while chemotherapy is usually not recommended...
for elderly patients [25], and most patients are not particularly sensitive to these drugs. Targeted therapy has emerged as a promising treatment strategy in recent years, with trastuzumab, targeted at human epidermal growth factor receptor-2 (HER2), and ramucirumab, targeted at vascular endothelial growth factor receptor-2 (VEGFR-2), being approved by the Food and Drug Administration [26, 27]. However, HER2 is only overexpressed in 13–22% of patients with gastric cancer [28, 29], underlining the necessity of discovering new treatment approaches.

Fig. 5 Anti-PSCA CAR-T cells suppressed tumor progression in MKN-28 models. a. Schematic representation depicting the time course of the experiment. b. Tumor volume was calculated according to the following formula: length × width²/2. c. Tumor weight of MKN-28 subcutaneously injected mice. Error bars denote the s.e.m., and the results were compared with one-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001. d. Percentage of T cells in the tumor of the MKN-28 models. e. Percentage of T cells in the PB of the MKN-28 models and representative FACS plots of the i.v group and the p.t group, respectively. f. Percentage of T cells in the spleen of the MKN-28 models and representative FACS plots of the i.v group and the p.t group, respectively. Error bars denote the s.e.m., and the results were compared with one-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001
The advent of CAR-T cell therapy triggered a paradigm shift in cancer immunotherapy [30]. The application of CAR-T cells in hematological malignancies has achieved compelling success [31], sparking considerable interest in in-depth research for this field. Until now, the effects obtained for the treatment of solid tumors have been relatively less encouraging [32]. A potential caveat is posed by the fact that solid tumors are heterogeneous, especially gastric cancer [33]. The lack of truly tumor-specific target antigens is one of the major obstacles. To provide more possibilities for clinical efficacy, we conducted a tentative experiment targeting PSCA in gastric cancer. We constructed a third-generation CAR composed of two costimulatory molecules as previously described [20] and confirmed the potential of PSCA as an ideal antigen for CAR-T cell therapy in gastric cancer. The third-generation CAR we applied herein composed of two costimulatory molecules, CD28 and DAP10. It has been corroborated by our lab that DAP10, the NKG2D-associated adaptor protein, is a perfect costimulatory molecule for CAR-T therapy. Incorporation DAP10 in the second-generation CAR-T cells could enhance anti-tumor capacity both in vitro and in vivo [34]. We assayed canonical T cell activation and memory related markers after coculturing anti-PSCA CAR-T cells with target cell lines. Anti-PSCA CAR-T cells exhibited upregulated activation markers and cytokine production profiles in an antigen-dependent manner. Importantly, we demonstrated that anti-PSCA CAR-T cells delivered by peritumoral injection successfully stunted tumor progression in vivo. However, anti-PSCA CAR-T cells given intravenously failed to have any therapeutic effects. Although CAR-T cells given intravenously demonstrated slightly augmented T cell level in the tumor, peripheral blood, and spleen in MKN-28 cell line based mouse model, there were no statistically significant differences. The absolute number of CAR-T cells remains low, especially within the tumor. Hence, we did not pay much attention to this phenomenon. We then analyzed T cell population in the tumor, the data showed that CAR positive T cell percentage moderately increased compared to that of the pre-infused CAR-T cells. It is also possible that there were free PSCA in the blood that masked the CAR-T cells. However, it has been previously reported that CARs can dissociate from dying tumor cells even more rapidly than TCRs [35]. Hence, we did not make it the primary cause of the impaired CAR-T cell cytotoxicity. Much more effort might be taken to investigate whether it is a general phenomenon or a rare case and the mechanism hidden behind. Statistical significance was observed in the tumor weight between the peritumoral injection group and the intravenous injection group in the BGC-823 model, while no differences were seen in the MKN-28 model. Presumably, the augmented peripheral blood and spleen T cell levels in the peritumoral injection group might have contributed to this deviation. Consistently, these data unveiled another challenge impeding CAR-T cell application in solid tumors, that is, the difficulty of T cells in migrating to and physically infiltrating into the tumor [36]. As previously reported, much of the current literature on CAR-T cell therapy for solid tumors pays particular attention to T cell trafficking. Kheng Newick (2016) noted that blocking protein kinase A (PKA) localization successfully augmented CAR-T cell trafficking and antitumor efficacy [37]. Along the same lines, Qin Gao (2019) found that DOC induced CD8+ T cell recruitment to the tumor microenvironment by enhancing the secretion of HMGB1 and CXCL11 [38], underlining another view that successful trafficking relies on an appropriate match between the chemokine receptors on T cells and the chemokines secreted by the tumors [39]. The evidence reviewed here seems to suggest a combination strategy, including anti-PSCA CAR-T cells and chemical drugs.

Altogether, our findings corroborated the feasibility and efficacy of anti-PSCA CAR-T cells against gastric cancer, thus providing a new solution for interpatient and intratumor heterogeneity.

**Conclusion**

This study identified PSCA as an ideal target for CAR-T cell therapy in GC and achieved impressive efficacy when using third-generation CAR-T cells for GC treatment. The results of this research reveal that anti-PSCA CAR-T cells can specifically eliminate target cells, both ex vivo and in vivo, implicating the potential of anti-PSCA CAR-T cells in treating GC patients in the clinic.

**Abbreviations**

ALL: Acute lymphoblastic leukemia; CAR: Chimeric antigen receptor; ET: Effector to target; ELSA: Enzyme-linked immune absorbance assay; GC: Gastric cancer; GM-CSF: Granulocyte-macrophage colony-stimulating factor; i.p.: Intraperitoneally; i.v.: Intravenous; IFNγ: Interferon-γ; IL-2: Interleukin-2; p.t.: Peritumoral; PB: Peripheral blood; PBMC: Peripheral blood mononuclear cells; PSCA: Prostate stem cell antigen; s.c.: Subcutaneous; scFv: Single-chain variable fragment

**Acknowledgments**

We would like to thank all the members in the list for experimental materials, technical assistance, helpful discussions, and comments.

**Authors’ contributions**

Conception and design: DW, PL, YY. Development of methodology: DW, JL, RZ, ZW, DZ, JS. Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): DW, JL, RZ, QW, SL, YL, SW, PL, YY. Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): DW, JL, RZ, PL, YY. Writing, review, and/or revision of the manuscript: DW, JL, RZ, PL, YY. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): YY, PL. Study supervision: PL, YY. All authors read and approved the final manuscript.

**Funding**

This study is supported by the National Natural Science Foundation of China (NSFC), No. 81961128003; The Strategic Priority Research Program of the Chinese Academy of Sciences, Grant No. XDB19030205; Guangdong
Provincial Significant New Drugs Development, No. 2019B020202003; The National Major Scientific and Technological Special Project for “Significant New Drugs Development”, No. SQ20182X090201; Guangdong Provincial Applied Science and Technology Research & Development Program, No. 2016B020370706; Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory, No. 2019SZK110105003; Science and Technology Planning Project of Guangdong Province, China (2017B030314056).

Availability of data and materials
All data generated or analyzed are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Healthy PBMCs providers, donors provided gastric cancer tissues and normal tissues, have given consent. All animal experiments were performed at the Laboratory Animal Center of the Guangzhou Institutes of Biomedicine and Health (GIBH). All procedures were approved by the Research Ethics Board of Guangzhou Institutes of Biomedicine and Health (GIBH).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of Life Sciences, University of Science and Technology of China, Hefei 230027, China. 2 Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China. 3 Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China. 4 University of Chinese Academy of Sciences, Shijingshan District, Beijing 100049, China. 5 Institute of Hematology, Medical College, Jinan University, Guangzhou 510632, China. 6 Hefei Institute of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.

Received: 5 November 2019 Accepted: 2 January 2020

Published online: 28 January 2020

References
1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354.
2. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer. 2004;7(1):9–16.
3. Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132.
4. Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23(5):430–50.
5. Zhang C, Liu J, Zhong JF, Zhang X. Engineering car-t cells. Biomark Res. 2017;5(1):22.
6. Newick K, Moon E, Albelida SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncol. 2016;3:16006.
7. Shum T, Kruse RL, Rooney CM. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther. 2018;18(6):553–64.
8. Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018;6:4.
9. Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.
10. Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018;11(1):22.
11. Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer immunotherapy workshop in Beijing. J Hematol Oncol. 2018;11(1):142.
12. Wenqi D, Li W, Shanhan C, Bei C, Yafei Z, Feihu B, Jie L, Daiming F. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol. 2009;135(9):1277–85.
13. Jung H, Jun KH, Jung JH, Chin HM, Park WB. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res. 2011; 167(2):185–91.
14. Padmanabhan N, Ushijima T, Tan P. How to stomach an epigenetic insult the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol. 2017;14(8):467.
15. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res. 2010;16(14):5353–8.
16. Priceman SJ, Gerds TA, Tilakawadane D, Kennewick KT, Murad JP, Park AK, Jeang K, Yamaguchi Y, Yang X. Unravel R. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764.
17. Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, Li B, Lin S, Wang S, Wu Q. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722.
18. Zhao X, Wang F, Hou M. Expression of stem cell markers nanog and PSCA in gastric cancer and its significance. Oncol Lett. 2016;11(1):442–8.
19. Olafsen T, Gu Z, Sherman MA, Leyton JM, Witkowski ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007;30(4):396–405.
20. Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019;12(1):18.
21. Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D’Ericon L, Menegon S, Moya-Rull D. A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. Cancer Res. 2019;2019:11166.
22. Wadhwa R, Song S, Lee J-S, Yao Y, Wei Q, Alani JA. Gastric cancer—molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10(11):663.
23. Liu D, Mehta D, Kaur S, Kumar A, Panik K, Chawla L, Patel S, Devi A, Saha A. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018;11(1):138.
24. Jeong O, Park Y-K. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer. 2011;11(2):69–77.
25. Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in elderly patients with gastric cancer. J Cancer. 2016;7:188.
26. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2010;17(1):14–7.
27. Casak SJ, Fashohin-Aje I, Lemory SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H. FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res. 2015;21(15):3732–6.
28. Meza-Junco J, Au H-J, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res. 2011;3:57.
29. Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, Romagnoli S, Bosari S, HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 2013;26(6):816.
30. Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for T therapy. J Hematol Oncol. 2019;12(1):169.
31. Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12(1):17.
32. Li D, Li X, Zhou W-L, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han W-D. Genetically engineered T cells for cancer immunotherapy. Signal Transduction Targeted Ther. 2019;4:1–17.
33. Patil DT, Rubin BP. Genetics of gastrointestinal stromal tumors: a heterogeneous family of tumors? Surg Pathol Clin. 2015;8(3):515–24.
34. Zhao R, Cheng L, Jiang Z, Wei X, Li B, Wu Q, Wang S, Lin S, Long Y, Zhang X, Wu X, Du X, Pei D, Liu P, Li Y, Cui S, Yao Y, Li P. DNA-activating protein co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. Oncoimmunology. 2019;8(11):e1909173.
35. Watanabe K, Kurumitsu S, Posey AD Jr, June CH. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the Knowns and unknowns of CAR T cell biology. Front Immunol. 2018;9:2486.
36. Castellarin M, Watanabe K, June CH, Koss CC, Posey AD. Driving cars to the clinic for solid tumors. Gene Ther. 2018;25(3):165.
37. Newick K, O’Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, Albelda SM. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization. Cancer Immunol Res. 2016;4(6):541–51.

38. Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, Huang L, Yang Y, Zhou B, Yue D. Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer. 2019;7(1):42.

39. Newick K, O’Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.